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Abstract 
Rationale: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a threat to humanity. 
However, no specific therapy has been established for this disease yet. We conducted a systematic review to 
highlight therapeutic agents that might be effective in treating COVID-19. 
Methods: We searched Medline, Medrxiv.org, and reference lists of relevant publications to identify articles of 
in vitro, in vivo, and clinical studies on treatments for severe acute respiratory syndrome (SARS), Middle East 
respiratory syndrome (MERS), and COVID-19 published in English until the last update on October 11, 2020. 
Results: We included 36 studies on SARS, 30 studies on MERS, and 10 meta-analyses on SARS and MERS in 
this study. Through 12,200 title and 830 full-text screenings for COVID-19, eight in vitro studies, 46 randomized 
controlled trials (RCTs) on 6,886 patients, and 29 meta-analyses were obtained and investigated. There was no 
therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19. 
Remdesivir showed a therapeutic effect for COVID-19 in two RCTs involving the largest number of total 
participants (n = 1,461). Other therapies that showed an effect in at least two RCTs for COVID-19 were 
sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), IFN-β1b (n = 193), and convalescent plasma therapy (n = 
126). 
Conclusions: This review provides information to help establish treatment and research directions for 
COVID-19 based on currently available evidence. Further RCTs are required. 










Coronavirus disease 2019 (COVID-19) refers to a 
respiratory syndrome caused by infection with severe 
acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2), an RNA virus belonging to the Coronaviridae 
family. Ever since the disease was first reported in 
Wuhan, China in December 2019, it has spread 
rapidly around the world. On October 28, 2020, a total 
of 43,766,712 SARS-CoV-2 cases were reported 
worldwide, of which 1,163,459 died [1]. Clinical 
manifestations range from being asymptomatic to 
pneumonia and acute respiratory distress syndrome 
(ARDS). Although estimations of case-fatality rate are 
different for COVID-19, there appears to be a high 
rate of a severe disease course or death, mainly in 
patients with advanced age or underlying diseases [2, 
3]. Current case fatality rates are 2.2% in Africa, 3.2% 
in Americas, 2.5% in Eastern Mediterranean Region, 
3.2% in Europe, 1.6% in South-East Asia, and 2.1% in 
Western Pacific Region [1], whereas the case fatality 
rate of SARS and Middle East respiratory syndrome 
(MERS), which are coronavirus respiratory 
syndromes similar to COVID-19 were 11% [4] and 
34% [5], respectively. 
There are currently no specific established 
treatments for COVID-19. Since the outbreak of 
COVID-19, numerous studies have been conducted 
during the past months; however, it is difficult to 
extract information from these extensive studies, 
synthesize the results, and apply them in practice. In 
fact, it would be almost impossible for front-line 
medical practitioners to be able to absorb the 
considerable number of reports being released on a 
daily basis and immediately translate the findings 
into practice during this medical crisis. 
For this reason, we summarized the in vivo, in 
vitro, and clinical research results related to potential 
therapies of COVID-19 and further integrated the 
results with previously reported results from SARS 
and MERS. We aimed to provide useful information 
for the establishment of treatment and research 
directions for COVID-19. 
Methods 
Literature search strategy and study selection 
We adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
statement. Two investigators (YJH and JIS) manually 
searched Medline for literature regarding therapeutics 
for SARS, MERS, and COVID-19. Only publications in 
English were included, with the exception of an 
individual study used within a meta-analysis. 
In order to complete this review in a timely 
manner during this pandemic, we first searched the 
meta-analyses or systematic reviews on SARS and 
MERS from inception to March 31, 2020 using the 
following search terms (“severe acute respiratory 
syndrome”, “SARS”, “Middle East respiratory 
syndrome”, or “MERS”) and (“meta”[title] or 
“systematic” [title]). After reading the full-text of 
articles obtained as a result of this search, we also 
investigated the in vitro, in vivo, and human studies on 
therapeutics of SARS or MERS that were included in 
them. Next, we conducted an additional search using 
the following search terms for the parts that were 
considered to be necessary for replenishment: 
[(“severe acute respiratory syndrome” or “SARS”) 
and (“remdesivir”, “nelfinavir”, “interferon beta”, or 
“chloroquine”)] or [(“Middle East respiratory 
syndrome” or “MERS”) and (“remdesivir”, 
“lopinavir”, “ritonavir”, “interferon alpha”, 
“interferon beta”, “convalescent plasma”, 
“chloroquine”, or “corticosteroid”)] (Figure 1). 
Moreover, in order to search for studies on 
COVID-19, a search was performed through the 
following search algorithm until the last update on 
May 7, 2020: ((wuhan[All Fields] and (“corona-
virus”[MeSH Terms] or “coronavirus”[All Fields])) 
and 2019/12[PDAT]: 2030[PDAT]) or 2019-nCoV[All 
Fields] or 2019nCoV[All Fields] or COVID-19[All 
Fields] or SARS-CoV-2[All Fields]. In addition, a 
search for randomized controlled trials (RCTs) on 
COVID-19 was also performed using the following 
search terms until the last update on October 9, 2020: 
((((wuhan[All Fields] and (“coronavirus”[MeSH 
Terms] or “coronavirus” [All Fields])) and 2019/12 
[PDAT]: 2030[PDAT]) or 2019-nCoV[All Fields] or 
2019nCoV [All Fields] or COVID-19[All Fields] or 
SARS-CoV-2[All Fields]) and (random 
[Title/Abstract] or randomization [Title/Abstract] or 
randomized [Title/Abstract] or randomized 
[Title/Abstract] or trial[Title]). To include a more 
sufficient amount of RCTs, a search for preprint RCTs 
through the database of Medrxiv.org was performed 
by conditions that include the following search terms 
in the titles until the last update on October 11, 2020: 
[“COVID” and (“random”, “controlled”, or “trial”)] 
or [“coronavirus” and (“random”, “controlled”, or 
“trial”)]or [“cov” and (“random”, “controlled”, or 
“trial”)]. A search for meta-analyses of treatment for 
COVID-19 was performed using the following search 
terms until the last update on October 11, 2020: 
((((wuhan[All Fields] and (“coronavirus”[MeSH 
Terms] or “coronavirus”[All Fields])) and 
2019/12[PDAT]: 2030[PDAT]) or 2019-nCoV[All 
Fields] or 2019nCoV[All Fields] or COVID-19[All 
Fields] or SARS-CoV-2[All Fields]) and (meta[Title]) 
(Figure 2). 






Figure 1. Flowchart of article selection process for SARS and MERS. SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; RCT: 
randomized controlled trial. *Two overlapped with in vitro studies on SARS; †One overlapped with an in vitro study on SARS each; ‡One overlapped with in vitro studies on MERS. 
 
Figure 2. Flowchart of article selection process for COVID-19. COVID-19: coronavirus disease 2019; PCR: polymerase chain reaction; RCT: randomized controlled 




Two investigators (YJH and JIS) identified the 
eligible studies by screening the titles and abstracts 
independently. Any disagreement was resolved by 
discussion and consensus among review authors. For 
non-human research, eligibility criteria for inclusion 
were (1) studies on SARS-CoV, MERS-CoV, or 
SARS-CoV-2 and (2) studies in which inoculation of 
virus preceded administration of therapeutic agents. 
For human research, eligibility criteria were 
organized in accordance with the Participants, 
Interventions, Comparisons, and Outcomes (PICO) 
reporting structure. 






We included studies on individuals with SARS, 
MERS, or COVID-19 who were diagnosed by 
validated methods using real time reverse 
transcription polymerase chain reaction (PCR) [6]. We 
excluded studies that were performed exclusively in 
children. According to the 7th edition of the Chinese 
clinical guidance for COVID-19 pneumonia, treatment 
with corticosteroids, tocilizumab, or convalescent 
plasma was recommended for patients with severe or 
progressive COVID-19 [7]. Therefore, when a 
non-RCT was included in a meta-analysis and 
targeted any of these treatment forms for patients 
with different severity of COVID-19, only the study 
analyzing the results of multivariate analysis 
conducted in the original research was included. In 
the case of meta-analyses on angiotensin-converting 
enzyme inhibitor (ACEI) or angiotensin receptor 
blocker (ARB) for COVID-19, studies that did not 
include participants selectively according to the 
presence of hypertension were excluded because it 
was thought that a mixture of participants with and 
without hypertension would affect the treatment 
outcome. 
Interventions 
We considered the pharmacological, immuno-
logical, or miscellaneous therapies administered after 
the onset of infection. Multiple therapeutic agents in 
combination were also included. Types of respiratory 
support, mechanical ventilation (MV) strategy, 
extracorporeal therapy, and radiation therapy were 
not target interventions in this study. The exclusion 
criteria were studies on (1) immunization or 
chemoprophylaxis, (2) Chinese medicine, or (3) other 
topics, such as epidemiology, without dealing with 
therapeutic interventions. We also excluded 
non-RCTs that did not specify the number of patients 
in the intervention group. 
Comparisons 
Control interventions relevant to the general 
treatment of respiratory infection (e.g., placebo or 
usual medications) or other therapeutic agents that 
could be candidates for the study intervention were 
included. 
Outcomes 
Studies reporting on mortality, intensive care 
unit (ICU) admission, disease progression, discharge 
rates, or improvement in the chest radiograph in the 
intervention/entire patient group or control group 
were included. 
Study design 
Because RCTs on SARS or MERS performed to 
date were not sufficient, any RCT, study in 
prospective or retrospective cohort design, case- 
control design, or case series published as an article in 
a scientific journal were eligible. In the case of 
non-RCTs, studies with a total of 10 or more patients 
were included, except for relatively rare treatment 
forms that had not been administered in dozens of 
patients to date. For COVID-19, only RCTs were 
eligible except of studies included in a meta-analysis. 
Data extraction 
Two investigators (YJH and JIS) collected 
information on the total number of patients and the 
number of patients in the intervention group, time 
range of enrollment or at the time of diagnosis or 
hospitalization, intervention and control therapy used 
in the study, and the outcome among the intervention 
and the control group. 
Classification of studies and interpretation of 
results 
In order to interpret the results of in vitro studies, 
50% maximal effective concentration (EC50) less than 
10 μM or selectivity index (SI) greater than 10 was set 
as a criterion for determining whether a particular 
drug has therapeutic potential against the virus of 
interest. 
The results of RCTs and meta-analyses were 
categorized as follows, depending on whether the 
therapeutic agent was effective against COVID-19. 
Effective: The treatment group showed superior 
results for major outcomes (mortality, ICU admission, 
disease progression, discharge, clinical improvement, 
or improvement in the chest radiograph) with a 
statistical significance (P < 0.05). 
Possible effect: The major outcome of the 
treatment group was not significantly worse (P > 
0.05), and the results for other outcomes other than 
the major outcome was superior in the treatment 
group with a statistical significance (P < 0.05). 
Not effective: The results for any outcome did 
not show a significant difference between the 
treatment and the control group (P > 0.05). 
Possible harm: The treatment group did not 
show statistically superior results for major outcomes 
(P > 0.05), and the results for other outcomes were 
worse with a statistical significance (P < 0.05). 
Harmful: The treatment group showed 
statistically inferior results for the major outcome (P < 
0.05). 






Systematic search results 
Through Medline search, a total of 10 
meta-analyses on SARS (n = 5) [8-12], MERS (n = 3) 
[13-15], and both (n = 2) [16, 17] were obtained and 
investigated. After investigating the original texts of 
in vitro, in vivo, and clinical studies cited in these 
meta-analyses, an additional Medline search was 
performed when the clinical study obtained by the 
search seemed to be insufficient for therapeutic agents 
that showed positive results from in vitro or in vivo 
studies. Through this process, 36 and 30 eligible 
articles on SARS and MERS were obtained, 
respectively: 20 in vitro, five in vivo studies (two 
overlapping with in vitro studies on SARS), 13 human 
non-RCTs (one overlapping with an in vitro study on 
SARS), and one RCT on SARS; and 15 in vitro (one 
overlapping with an in vitro study on SARS), seven in 
vivo studies (one overlapping with in vitro studies on 
MERS), and 10 human non-RCTs on MERS. In 
addition, as a result of searching the database of 
Clinicaltrials.gov, we identified one RCT on SARS 
that was not completed after registration, and one on 
MERS. Of these, an RCT of lopinavir/ritonavir plus 
ribavirin in the treatment of SARS [18] had not yet 
started recruiting participants since it was registered 
in December 2007, and the current status was 
unknown; and another RCT of lopinavir/ritonavir 
and interferon (IFN)-β1b in the treatment of MERS 
[19] was completed on May 20, 2020 (Figure 1). 
A total of 12,200 articles on COVID-19 were 
identified through a Medline and Medrxiv.org search. 
After full-text screening of 830 articles, 83 eligible 
articles on COVID-19 were obtained: eight in vitro 
studies, 46 RCTs on 6,886 patients, and 29 
meta-analyses (Figure 2). 
The research results for SARS and MERS for each 
therapeutic agent are described in Table 1, and the 
research results for COVID-19 are described in Table 
2, 3 & Table 4, and Table S1. 
Antiviral agents 
Remdesivir 
Remdesivir showed effects in multiple 
non-human studies on SARS or MERS (Table 1), and 
in one in vitro study on COVID-19 (Table 2). Four 
RCTs on remdesivir for COVID-19 have been 
published to date. One of them was a large-scale RCT, 
with 538 and 521 participants in the treatment and the 
control group, respectively, and remdesivir was 
administered to the treatment group for 10 days. The 
time to recovery was shorter in the treatment group 
compared to the control group {11 [95% confidence 
interval (CI) 9–12] vs. 15 [13–19] days; relative risk 
(RR) for recovery 1.32, 95% CI 1.12 to 1.55; P < 0.0001} 
and the odds ratio (OR) for the improvement of the 
ordinal score on day 15 was 1.50 (95% CI 1.18 to 1.91, 
P = 0.001). There was no significant difference in the 
14-day mortality rate between the two groups. 
However, when compared among the participants 
with a baseline ordinal score of 5 requiring oxygen 
supplementation, the 14-day mortality rate of the 
treatment group was significantly lower (4 out of 222 
[2%] vs. 19 out of 199 [10%]; hazard ratio [HR] 0.22, 
95% CI 0.08 to 0.58) [20]. In another RCT on severe 
COVID-19, the 28-day mortality rate did not differ 
between remdesivir-treated patients and controls [21] 
(Table 3). According to a meta-analysis for these two 
RCTs [20, 21], the RR for clinical recovery was 1.17 
(95% CI 1.07 to 1.29) [22] (Table 4). 
The other two RCTs for COVID-19 were 
performed with different administration periods of 
remdesivir, five and ten days, respectively. Among 
them, the 5-day treatment group showed better 
clinical status distribution on the 7-category ordinal 
scale on day 11 (OR 1.65, 95% CI 1.09 to 2.48) in one 
RCT for moderate COVID-19 [23]. In another RCT for 
severe COVID-19, the incidence of serious adverse 
events was lower in the 5-day treatment group than in 
the 10-day treatment group (42 out of 200 [21%] vs. 68 
out of 197 [35%]; difference 10.8%, 95% CI 2.4% to 
19.2%) [24] (Table 3). In a meta-analysis involving one 
of these RCTs [24] and another unreported RCT [25], 
the OR for clinical recovery in the 5-day course of 
treatment was 1.33 (95% CI 1.01 to 1.76) compared to 
the 10-day course of treatment [26] (Table 4). 
Sofosbuvir and daclatasvir 
A combination of sofosbuvir/daclatasvir 
showed an effect in two RCTs on COVID-19 which 
were conducted in Iran. In one RCT, the cumulative 
incidence of hospital discharge was higher (P = 0.041) 
and the duration of hospitalization was shorter (6 
[interquartile range (IQR) 4–8] vs. 8 days [5–13]; P = 
0.029) in the treatment compared to the control group 
[27]. In another RCT, the cumulative incidence of 
recovery was higher in the treatment compared to the 
control group (P = 0.033) [28] (Table 3). 
Favipiravir 
The results of two in vitro studies on favipiravir 
for COVID-19 were unfavorable [29, 30]. However, in 
a Russian RCT on favipiravir for moderate COVID-19, 
the rate of negative results of virus PCR on day 5 was 
higher in the treatment than in the control group (25 
out of 40 [63%] vs. 6 out of 20 [30%]; P = 0.018) [31]. In 
another RCT on mild COVID-19, the hospital 
discharge rate of participants who received 
favipiravir from the first day of enrollment was higher 





than that of participants who received favipiravir 
starting from one week after enrollment (HR 2.68, 95% 
CI 1.67 to 4.29) [32] (Table 3). 
Umifenovir 
Umifenovir showed an effect in an in vitro study 
on COVID-19 [33] (Table 2). In an RCT comparing a 
combination of umifenovir and lopinavir/ritonavir 
with standard treatment, the group receiving the 
treatment with umifenovir did not show better 
outcome than the control group in terms of clinical 
deterioration or viral clearance [34] (Table 3). On the 
other hand, a meta-analysis that included this RCT 
[34] and four observational studies on COVID-19 
demonstrated that umifenovir treatment enhanced 
the rate of viral clearance on day 14 (RR 1.27, 95% CI 
1.04 to 1.55; P = 0.02; I2 = 63%; n = 683) [35] (Table 4). 
 
Table 1. Summary of studies evaluating therapeutics for SARS and MERS 
Therapeutics SARS MERS 
In vitro In vivo Human In vitro In vivo Human 
Antiviral agents       
Ribavirin 4 studies  
[36, 130-132] 
2 studies [133, 134] 
 4 studies [135-138] 1 study [139]   
Remdesivir 1 study [140] 1 study [140] 4 studies [38, 140-142] 2 studies [38, 143]   
Lopinavir 1 study [130]  
2 studies [48, 50] 
  2 studies [38, 51] 
1 study [95] 
  
Ritonavir 1 study [48]      
Oseltamivir   1 study [136]   1 study [144] 
Nelfinavir 1 study [48] 
1 study [50] 
1 study [50]     
Interferon IFN-α (8 studies)  
[50, 130, 132, 134, 
145-148]; 
IFN-β (8 studies)  
[130, 132, 145, 147-151] 
IFN-α/IL-1β (1 study) 
[152] IFN-α B/D, 
rintatolimod† (1 study) 
[50]. 
IFN-α (1 study): more 
effective than 
corticosteroids [153]. 
IFN-α (1 study) [139]; IFN-β  
(2 studies) [154, 155]. 
IFN-β (2 studies) 
[39, 156]§ 
1 study [14]‡ 
IFN-α-n3 (1 study) [50] 
Combination therapy based on antiviral agents or interferon     
Ribavirin/IFN IFN-α (1 study) [130]; 
IFN-β (2 studies) [130, 
131]. 
  IFN-α (1 study) [157]  IFN-α (2 studies)  
CFR 6/20 (30%) vs. 
17/24 (71%) (P = 
0.01) [158] 
CFR 14/61 (23%) vs. 
2/2 (100%) (P = 0.01) 
[159]. 






1 study [36]      
Ribavirin  
plus L/r 
  Registered RCT 
(not yet recruiting) [18] 
   
L/r 3 studies 
[36, 99, 130] 
1 study [48] 
 2 studies:  
Rates of ARDS/death 
(2% vs. 29%, P = 0.001) 
[36] 
CFR 2% vs. 16% (P < 
0.05) [37]. 
1 study [38] 1 study [39]  
L/r plus IFN-β    2 studies [38, 39] Ongoing RCT [19]  
Ribavirin/ 
corticosteroids 
 1 study earlier 
administration [163] 
    
IFN-α/ 
corticosteroids 
 1 study [153]     




   1 study [156]   
Antibiotics       
Macrolide     1 study: mortality 
and viral clearance 
[165] 
 
4-Aminoquinoline      
Chloroquine 3 studies [50, 166, 167] 1 study [50]  1 study [51] 
 1 study [52] 
  
Amodiaquine 1 study [50] 1 study [50]     
Corticosteroids   4 studies 





 Inconclusive (2 
studies); 
Delay in viral 
clearance (HR 0.35; 
95% CI 0.17-0.72), 
not associated with 
 





Therapeutics SARS MERS 
In vitro In vivo Human In vitro In vivo Human 
was better than 3 other 
groups (no steroid, 
hydrocortisone, or 
pulse therapy) [65]. 
mortality [61] 
CFR 6/13 (46%) vs. 
2/19 (11%) (P = 0.04) 
in univariate 
analysis [144]. Inconclusive (2 studies) 
[59, 60] 
Early administration – 
higher plasma viral 
load, no difference in 
severity [59]*  
Possible adverse effect 
(1 study): osteonecrosis 
[10]‡. 
Immunotherapy      
Convalescent 
plasma 
  Inconclusive (1 study)  
CFR [0/1 (0%) vs. 2/28 
(7%)] and [0/19 (0%) 
vs. 5/21 (24%) in 2 
comparative studies, 
and 0/1, 0/1, 0/3, and 
10/80 in 4 
non-camparative 
studies [12]‡ 
1 study [168] Inconclusive  
(1 study): 







 201 [170]  m336 [168], hMS-1 [171], 4C2h 
[172],  
HR2P-M2 [156].  
  
Other drugs β-D-N4-hydroxycytidine 
[50]; calpain inhibitor VI 
[50] 
Camostat [173]  Camostat [80], loperamide [51], 
chlorpromazine [51, 52, 174],  
imatinib [174, 175], 
saracatinib [80, 175], 
baricitinib [80], dasatinib [174], 
cyclosporine [176], EST [80], 
cathepsin L/K inhibitor [80],  
gemcitabine/toremifene/ 
triflupromazine [174], 
mycophenolic acid [155]. 
  
β-D-N4-hydroxy-
cytidine [50]; calpain 
inhibitor VI [50] 
 Toremifene [52]   
(Effective; bold Not effective). In the outcome description, the former is the data of the treatment group and the latter is the data of the control group. 
CFR: case-fatality ratio; CI: confidence interval; EST: (23,25)-trans-epoxysuccinyl-l-leucylamindo-3-methylbutane ethyl ester; HR: hazard ratio; ICU: intensive care unit; IFN: 
interferon; L/r: lopinavir/ritonavir; MERS: Middle East respiratory syndrome; OR: odds ratio; RCT: randomized controlled trial; RR: risk ratio; SARS: severe acute 
respiratory syndrome; 
*This study is the only published randomized controlled trial in this table. †A mismatched double-stranded RNA interferon inducer. ‡Meta-analysis. §Intranasal 
administration. 
 
Table 2. Therapeutic agents that showed effects against SARS-CoV-2 in in vitro studies 
Therapeutics First author Findings  Conclusion 
Antiviral agents    
Umifenovir Wang [33] EC50 = 4.11 μM; CC50 = 31.79 μM; SI = 7.73 Potent 
Remdesivir Wang [29] EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87 Potent 
 Choy [30] EC50 = 26.9 μM; CC50 > 100 μM Not potent 
Nelfinavir Musarrat [49] Complete inhibition of SARS CoV-2 mediated cell fusion at 10 μM Potent 
Antiparasitic agents    
Ivermectin Caly [177] 5000-fold reduction in viral RNA at 48h after a single administration (IC50 < 2mM) Potent 
Emetine Choy [30] EC50 = 0.5 μM; CC50 = 56.46 μM Potent 
4-aminoquinoline (anti-malarial agents)   
Chloroquine Wang [29] EC50 = 1.13 μM; CC50 > 100 μM; SI > 88.5 Potent 
 Yao [53] Incubation time may influence antiviral activity (24h EC50 = 23.9 μM; 48h EC50 = 5.47 μM). Potent 
 Liu [54] EC50 = 2.71 (MOI = 0.01), 3.81 (0.02), 7.14 (0.2), 7.36 (0.8) μM; CC50 = 273.2 μM Potent 
Hydroxychloroquine Yao [53] 24h EC50 = 6.14 μM; 48h EC50 = 0.72 μM Potent 
 Liu [54] EC50 = 4.51 (MOI = 0.01), 4.06 (0.02), 17.31 (0.2), 12.96 (0.8) μM; CC50 = 249.5 μM Potent 
Other agents    
Homoharrngtonine Choy [30] EC50 = 2.14 μM; CC50 = 59.75 Potent 
Nitazoxanide Wang [29] EC50 = 2.12 μM; CC50 > 35.53 μM; SI > 16.76 Potent 
Immunotherapy    
EK1C4 Xia [178]  IC50 = 36.5 nM; CC50 > 5 μM; SI > 136 Potent 
CC50: 50% cytotoxic concentration; COVID-19: coronavirus disease 2019; EC50: 50% maximal effective concentration; MOI: multiplicity of infection; SARS-CoV-2: severe acute 









Table 3. Summary of RCTs evaluating therapeutics for COVID-19 
Therapeutics (daily dosage 
mg) [Common treatment 
applied to all participants] 
First author Condition Region Period of 
enrollment 
No. of participants 
(treatment - 
control group) 
Outcome of patients or findings: treatment group vs. 
control group 
(number of participants or the median value [IQR]) 
Conclusion 
Antiviral agents        
Remdesivir        
200 mg (day 1); 100 mg  
(day 2-10) vs. standard 
treatment 






541 - 521 Improvement in the ordinal score on day 15: OR 1.50, 
95% CI 1.18 to 1.91 (P = 0.001) 
14-day mortality: 32 (6%) vs. 54 (10%) (HR 0.70, 95% CI 
0.47 to 1.04) 
14-day mortality in patients with a baseline ordinal 
score of 5 (requiring oxygen): 4/222 (2%) vs. 19/199 
(10%) (HR 0.22, 95% CI 0.08 to 0.58)  
Time to recovery: 11 (95% CI 9–12) vs. 15 (13–19) days 
(RR for recovery 1.32, 95% CI 1.12 to 1.55; P < 0.0001). 
Effective 
A: 200 mg (day 1);  
100 mg (day 2-10) 
B: 200 mg (day 1);  
100 mg (day 2–5). 
C: Standard treatment. 








Better clinical status distribution on the 7-category 
ordinal scale on day 11: OR (B vs. C) 1.65 (95% CI 1.09 to 
2.48)  




200 mg (day 1); 100 (day 
2-10) vs. standard treatment 
Wang [21] Severe China Feb 6- 
Mar 12 
158 - 78 28-day mortality: 22 (14%) vs. 10 (13%) 
Time to clinical improvement (a 2-point reduction on a 
6-category ordinal scale, or discharge from hospital): 21 
[13–28] vs. 23 [15–28] days (HR 1.23, 95% CI 0.87 to 1.75) 
Not effective 
A: 200 mg (day 1); 100 (day 
2-5) 
B: 200 mg (day1); 100 (day 
2-10) 




200 (A)  
197 (B) 
Clinical improvement of 2 points or more on a 
7-category ordinal scale within 14 days: 129 (A, 64%) vs. 
107 (B, 54%) (difference -6.5%, 95% CI -15.7% to 2.8%) 
14-day mortality among patients receiving MV or 
ECMO: 10/25 (A, 40%) vs. 7/41 (B, 17%) 
Serious adverse event: 42 (A, 21%) vs. 68 (B, 35%) 
(difference 10.8%, 95% CI 2.4% to 19.2%). 
Favors 5-day 
treatment 
Sofosbuvir/daclatasvir        
400 mg/60 mg for 14 days 
vs. standard treatment 
[hydroxychloroquine with 
or without lopinavir 
/ritonavir] 
Sadeghi [27] Moderate/ 
severe 
Iran Mar 26- 
Apr 26 
33 - 33 Duration of hospitalization: 6 [4–8] vs. 8 days [5–13] (P 
= 0.029) 
The cumulative incidence of hospital discharge was 
higher in the treatment group (P = 0.041). 
Clinical recovery within 14 days: 29 (88%) vs. 22 (67%) 
(P = 0.076). 
Effective 







Moderate Iran Mar 20- 
Apr 8 
24 - 24 ICU admission: 0 (0%) vs. 4 (17%) (P = 0.109)  
Hospital mortality 0 (0%) vs. 3 (13%) (P = 0.234). 
The cumulative incidence of recovery was higher in the 
treatment group (P = 0.033). 
Effective 
Favipiravir        
A: 3,200 mg (day 1); 1,200  
(day 2–14); 
B: 3,600 day (day 1); 1,600  
(day 2–14); 
C: Standard treatment. 
Ivashchenko 
[31] 
Moderate Russia Apr–May 20 (A)  
20 (B)  
20 (C) 
Discharge or achievement of score 2 on WHO-OSCI by 
day 15: 13 (A, 65%), 17 (B, 85%), and 17 (C, 85%) 
Viral clearance on day 5: 25/40 (A and B, 63%) vs. 6/20 
(C, 30%) (P = 0.018) 
Possible 
effect 
3,600 mg (day 1); 1,600 mg 
(day 2–10) vs. 3,600 mg (day 
6); 1,600 mg (day 7–15) 
Doi [32] Mild Japan Mar 2- 
May18 
36 - 33 Time to discharge from the hospital: 14.0 vs.21.5 days 
(HR 2.68, 95% CI 1.67 to 4.29) 
Viral clearance on day 6: 67% vs. 56% (adjusted HR 
1.42, 95% CI 0.76 to 2.62) 




Other antiviral agents        
Lopinavir (800)/ ritonavir 
(200) for 14 days vs. standard 
treatment 
Cao [40] Severe China Jan 18-Feb 
3 
99 - 100 28-day mortality: 19 (19%) vs. 25 (25%) (difference 
-5.8%; 95% CI -17.3% to 5.7%) 
Time to clinical improvement (a 2-point reduction on a 
7-category ordinal scale or discharge from hospital): 16 
[13–17] vs. 16 [15–18] days (HR 1.24, 95% CI 0.90 to 1.72) 
Hospital stay: 14 [12–17] vs. 16 [13–18] days (difference 
1, 95% CI 0 to 2) 
Not effective 
A: Lopinavir (400) /ritonavir 
(100) for 7–14 days  
B: Umifenovir (600) for 7–14 
days 
C: Standard treatment 
Li [34] Mild/ 
moderate 





Deterioration to severe/critical COVID-19 on day 7: 
8/34 (A, 24%), 3/35 (B, 9%), and 2/17 (C, 12%) (P = 
0.206) 
Time to viral clearance: 9.0 (A; SD 5.0), 9.1 (B; 4.4), and 
9.3 (C; 5.2) days (P = 0.981) 
Viral clearance within 7 days: 12/34 (A, 35%), 13/35 (B, 
37%), and 7/17 (C, 41% ) (P = 0.966). 
Not effective 
A: Ribavirin (2,000 mg 
loading; 1,200–1,800 mg for 
14 days)  
B: Lopinavir (800)/ritonavir 
(200)  
C: Ribavirin plus 
lopinavir/ritonavir  
Huang [41] Mild/ 
moderate 





Deterioration to severe COVID-19: 1 (A, 3%), 2 (B, 6%), 
and 2 (C, 6%) (P = 0.58) 
Time to viral clearance: 13.0 [9.0–25.5] (A), 12.0 [7.0–
19.0] (B), and 15.0 [9.3–17.8] (C) days (P = 0.42) 
Viral clearance on day 14: 17/33 (A, 52%), 22/36 (B, 
61%), and 15/32 (C, 47%). 
Not effective 
Azvudine (FNC) (5) vs. 
standard treatment 
Ren [45] Mild/ 
moderate 
China Feb 18–Feb 
29 
10 - 10 Time to radiological improvement was shorter in the 
treatment group (P = 0.0401). 
Viral clearance on day 6: 10 (100%) vs. 4 (40%) (P = 
0.0011). 
Effective 





Triazavirin (750 or 1,000 for 
7 days)‡ vs. standard 
treatment 




26 - 26 Clinical improvement§: 10 (39%) vs. 6 (23%) (RR 2.1, 
95% CI 0.6 to 7.0, P = 0.2) 
Time to clinical improvement§: 7 [6–15] vs. 12 [7–16] 
days (RR 2.0, 95% CI 0.7 to 5.6, P = 0.2). 
Not effective 
Darunavir (800)/cobicistat 
(150) for 5 days vs. standard 
treatment 
Chen [47] Mild China Jan 30–Feb 
6 
15 - 15 Worsening of chest CT findings: 7 (47%) vs. 4 (27%) (P = 
0.45) 
Viral clearance on day 7: 7 (47%) vs. 9 (60%) (P = 0.72). 
Not effective 
Hydroxychloroquine        
800 mg (day 1); 400 mg  
(day 2–7) vs. standard 
treatment 
Mitjà [179] Mild  Spain Mar 17–
Apr 28 
136 - 157 Number of hospitalized participants: 8 (6%) vs. 11 (7%) 
(RR 0.75, 95% CI 0.32 to 1.77); 
Time to the resolution of symptoms : 10 [4–18] vs. 12 
[6-21] days (P = 0.38); 
Reduction in viral load on day 7: -3.49 (SD 0.20) vs. -3.37 
(0.19) log10 copies/mL (difference -0.12, 95% CI -0.25 to 
0.5). 
Not effective 
1,200 mg (day 1–3); 800 mg 
(day 4–14) vs. standard 
treatment 
Tang [180] Mild/ 
moderate 
China Feb 11–Feb 
29 
75 - 75 Alleviation of symptoms by day 28¶: 60% vs. 67% 
(difference -7%, 95% CI -41% to 28%) 
Viral clearance by day 28: 56 (75%) vs. 53 (71%)  
Adverse events**: 21/70 (30%) vs. 7/80 (9%). 
Not effective 
800 mg (day 1); 400mg (day 
2–15) vs. standard treatment 
Abd-Elsalam
b [181]  
Not 
specified 
Egypt Mar–Jun 97 - 97 Initiation of MV: 4 (4%) vs. 5 (5%) (P = 0.75) 
28-day mortality: 6 (6%) vs. 5 (5%) (P = 0.77). 
Not effective 
1,400 mg (day 1); 600 mg 
(day 2–5) vs. standard 
treatment 




73 - 72 Change in symptom severity score over 14 days: 
-2.21(SE 0.23) vs. -2.10 (0.23) (P = 0.51). 
Not effective 
800 mg (day 1); 400 mg  




Mild Pakistan Apr 10–
May 31 
349 - 151 Disease progression‡‡: 11 (3%) vs. 5 (3%) (P = 0.865) 




400 mg for 5 days vs. 
standard treatment 
Chen [55]†† Mild/ 
moderate 
China Feb 4- 
Feb 28 
31 - 31 Improvement of chest CT scans on day 6: 25 (81%) vs. 
17 (55%) (P = 0.0476) 
Duration of fever: 2.2 (SD 0.4) vs. 3.2 (1.3) days (P = 
0.0008). 
Effective 
800 mg (day 1); 400 mg (day 
2–7) vs. standard treatment 
Chen [183]†† Mild/ 
moderate 
Taiwan Apr 1- 
May 31 
21 - 12 Clinical recovery (3 consecutive negative results of viral 
PCR and resolution of major symptoms) within 14 
days: 6/21 (29%) vs. 5/12 (42%) (P = 0.51) 
Time to viral clearance: 5 (95% CI 1 to 9) vs. 10 (2 to 12) 
days (P = 0.40) 
Viral clearance within 14 days: 17/21 (81%) vs. 9/12 
(75%) (P = 0.36). 
Not effective 
Azithromycin        
500 mg for 10 days vs. 
standard treatment 
Furtado [58] Severe Brazil Mar 28- 
May 19 
214 - 183 Worse clinical status on the 6-category ordinal scale on 
day 15: OR 1.36 (95% CI 0.94 to 1.97, P = 0.11)  
28-day mortality: 90 (42%) vs. 73 (40%) (HR 1.08, 95% CI 
0.79 to 1.47, P = 0.63). 
Not effective 




Sekhavati [57]  Not 
specified 
Iran Apr 24- 
May 8 
56 - 55 Length of hospital stay: 4.6 (SD 2.6) vs. 6.0 (SD 3.2) days 
(P = 0.02) 
Mortality: 0 (0%) vs. 1 (2%) (P = 0.495) 
ICU admission: 2 (4%) vs. 7 (13%) (P = 0.070). 
Effective 
Colchicine        
2 mg (day 1)§§; 1 mg (till 





Deftereos [70] Not 
specified 
Greece Apr 3- 
Apr 27 
55 - 50 Cumulative event-free 10-day survival rate: 97% vs. 
83% (P = 0.03) 
Deterioration by 2 points on a 7-category ordinal scale 
within 3 weeks: 1 (2%) vs. 7 (14%) (OR 0.11, 95% CI 0.01 
to 0.96, P = 0.046) 
Peak D-dimer concentration: 0.76 [0.41–1.59] vs. 0.92 
[0.68–2.77] μg/mL (P = 0.04). 
Effective 
1.5 mg (day 1–5); 1 mg (day 




Lopes [71]†† Moderate/ 
severe 
Brazil Apr 11- 
Jul 06 
17 - 18 Proportion of participants requiring supplemental 
oxygen on day 7: 6% vs. 39% (P = 0.01) 
Maintenance of hospitalization: 53% vs. 78% (on day 5), 
6% vs. 17% (on day 10) (P = 0.01) 
Duration of oxygen supplement: 3.0 [1.5–6.5] vs. 7.0 
[3.0–8.5] days (P = 0.02) 
Length of hospital stay: 6.0 [4.0–8.5] vs. 8.5 [5.5–11.0] 
days (P = 0.03). 
Effective 
Other agents        
Methylprednisolone (250 for 






Severe Iran Apr 20–
Jun 20 
34 - 28 Mortality: 2 (6%) vs. 12 (43%) (P < 0.001) 
Clinical improvement***: 32 (94%) vs. 16 (57%) (P = 
0.001) 
Time to clinical improvement***: 11.8 (SD 4.9) vs. 16.4 
(SD 6.9) (P = 0.003). 
Effective 
Telmisartan (160) for 14 days 
vs. standard treatment 






41 - 41 HR for discharge: 2.02 (95% CI 1.14 to 3.59) 
Time to discharge from the hospital: 9 vs. 15 days (P = 
0.0124) 
30-day mortality: 2/38 (5%) vs. 4/34 (12%) (P = 0.41) 
Serum CRP levels on day 5: 24.2 (SD 31.4) vs. 51.1 (44.8) 
mg/L (P < 0.05). 
Effective 
Enoxaparin (0.75–2 mg/kg 
for 4–14 days) vs. 
enoxaparin (40 or 80) or 
unfractionated heparin 
(15,000–22,500 IU)††† 
Lemos [75] Severe and 
intubated 
Brazil Apr–Jul 10 - 10 Successful liberation from MV by day 28: 8 (80%) vs. 3 
(30%) (HR 4.0, 95% CI 1.04 to 15.05, P = 0.031) 
Ventilator-free days: 15 [6–16] vs. 0 [0–11] days (P = 
0.028)]; 
28-day mortality: 1 (10%) vs. 3 (30%) (P = 0.264). 
Effective 
Calcifediol (0.532 on day 1; 







50 - 26 ICU admission: 1 (2%) vs. 13 (50%) (adjusted OR 0.03, 
95% CI 0.003 to 0.25). 
Effective 









CM4620-IE (Auxora: calcium 
release-activated calcium 
channel inhibitor) (2.0 
mg/kg/day continuous 
infusion on day 1; 1.6 
mg/kg/day on day 2–3) vs. 
standard treatment. 
Miller [79] Severe/ 
critical 
The US Apr 8- 
May 13 
20 – 10 IMV or death by day 30: 3/17 (18%) vs. 5/9 (56%) in 
participants with severe COVID-19 (HR 0.23, 95% CI 
0.05 to 0.96; P < 0.05) 
The mean difference in 8-point ordinal scale between 
groups was statistically significant at day 6 and day 9–
12 (P < 0.05). 
Effective 
Ruxolitinib (Janus- 
associated kinase inhibitors) 
(10) vs. standard treatment 
Cao [81] Severe China Feb 9- 
Feb 28 
20 - 21 Improvement of chest CT scans on day 14: 18 (90%) vs. 
13 (62%) (P = 0.0495) 
28-day mortality: 0 (0%) vs. 3 (14%) (P = 0.232) 
Time to clinical improvement (a 2-point reduction on a 
7-category ordinal scale or discharge from hospital): 12 
[10–19] vs. 15 [10–18] days (P = 0.147) (HR 1.669, 95% CI 
0.836 to 3.335) 
Time to lymphocyte recovery: 5 [2–7] vs. 8 [2–11] days 
(P = 0.033). 
Effective 
Leflunomide (DHODH 
inhibitor) (100 day 1–3; 20 




Moderate China Feb 20- 
Feb 28 
5 -5 Duration of viral shedding: 5 vs. 11 days (P = 0.046) 
The difference in the level of serum CRP measured 
before treatment and on day: 32 [5.6–not tested] vs.0 
[0-9.1] mg/L (P = 0.047). 
Possible 
effect 
Immunotherapy        
Interferon        
IFN-β1a (12 million IU 3 








Severe Iran Feb 29- 
Apr 3 
42 - 39 28-day mortality: 19% vs. 44% (P = 0.015) 
Rate of discharge from the hospital: 67% vs. 44% (OR 
2.5, 95% CI 1.05 to 6.37) 
Early administration of IFN-β1a reduced mortality (OR 
13.5, 95% CI 1.5 to 118). 
Time to clinical improvement: 9.7 ± 5.8 vs. 8.3± 4.9 days 
(P = 0.95). 
Effective 
IFN-β1b (3 doses of 8 million 
IU on alternate days) plus 
ribavirin (800) for 14 days vs. 
standard treatment 
[Lopinavir/ritonavir] 






86 - 41 Time to a NEWS2 of 0: 4 [3–8] vs. 8 [7–9] days (HR 3.92, 
95% CI 1.66 to 9.23) 
Time to a SOFA score of 0: 3.0 [1.0–8.0] vs. 8.0 [6.5–9.0] 
days (HR 1.89, 95% CI 1.03 to 3.49) 
Length of hospital stay: 9.0 [7.0–13.0] vs. 14.5 [9.3–16.0] 
days (HR 2.72, 95% CI 1.2 to 6.13) 
Time to viral clearance: 7 [5–11] vs. 12 [8–15] days (HR 
4.37, 95% CI 1.86 to 10.24, P = 0.001). 
Effective 
IFN-β1b (250 mcg on 
alternate days for 2 weeks) 
vs. standard treatment 
Rahmani [84] Severe Iran Apr 20- 
May 20 
33- 33 Discharge from hospital by day 14: 26 (79%) vs. 18 
(55%) (OR 3.09, 95% CI 1.05 to 9.11, P = 0.03) 
ICU admission: 14 (42%) vs. 22 (67%) (P = 0.04) 
Time to clinical improvement (a 2-point reduction on a 
6-category ordinal scale): 9 [6–10] vs. 11 [9–15] days (P = 
0.002). 
Effective 
Inhaled IFN-κ (2) plus TFF2 
(5) for 6 days vs. standard 
treatment  
Fu [85] Moderate China Mar 23- 
May 23 
40 - 40 Time to improvement of chest CT: 6.2 (95% CI 5.1–7.3) 
vs. 8.8 (95% CI 7.6-10.0) days (P = 0.002) 
Time to viral clearance: 3.8 (95% CI 2.1–5.5) vs. 7.4 (95% 
CI 4.6–10.2) days (P = 0.031). 
Effective 
A: Novaferon (40 mcg) 
B: Novaferon and lopinavir 
(800)/ritonavir (200) 
C: Lopinavir/ritonavir. 
Zheng [86] Moderate/ 
severe 





Viral clearance on day 6: 15/30 (A, 50%; P = 0.04) or 
18/30 (B, 60%; P = 0.0053) vs. 7/29 (C, 24%) 
Time to viral clearance: 6 (A, P = 0.417) or 6 (B, P = 
0.036) vs. 9 (C) days. 
Possible 
effect  
Convalescent plasma        
4-13 mL/kg vs. standard 
treatment 






52 - 51 Clinical improvement (a 2-point reduction on a 
6-category ordinal scale or discharge from hospital) 
within 28 days: 27 (52%) vs. 22 (43%) (HR 1.40, 95% CI 
0.79 to 2.49) 
Clinical improvement within 28 days for the 
participants with severe COVID-19: 21/23 (91%) vs. 
15/22 (28%) (HR 2.15, 95% CI 1.07 to 4.32)  
28-day mortality: 8 (16%) vs. 12 (24%) (OR 0.59, 0.22 to 
1.59) 
Viral clearance within 72 hours: 41 (87%) vs. 15 (38%) 









Moderate India Apr 22- 
Jul 14 
235 - 229 28-day mortality: 34 (15%) vs. 31 (14%) (adjusted OR 
1.06, 95% CI 0.61 to 1.83) 
Disease progression (PaO2/FiO2 < 100): 44 (19%) vs. 41 
(18%) (adjusted OR 1.09, 95% CI 0.67 to 1.77). 
Not effective 










43 - 43 60-day mortality: 6 (14%) vs. 11 (26%) (OR 0.95, 95% CI 
0.20 to 4.67) 
Improvement in WHO-OSCI on day 15: 25 (58%) vs. 25 
(58%) (OR 1.30, 95% CI 0.52 to 3.32). 
Not effective 






Spain Apr 4- 
Jul 10 
38 - 43 Initiation of MV or death by day 15: 0 (0%) vs. 6 (14%) 
(P = 0.03) 
28-day mortality: 0 (0%) vs. 4 (9%) (P = 0.06). 
Effective 




At risk for 
progression 
Chile May 10- 
Jul 18 
28 - 30 A composite of MV, hospitalization for > 14 days, or 
death: 9 (32%) vs. 10 (33%) (OR 0.95, 95% CI 0.32 to 2.84) 
13 participants (43%) from the deferred group received 
convalescent plasma based on clinical aggravation. 
Not effective 





Other immunotherapies        
rhG-CSF 5 mcg/kg (day 1–3) 
vs. standard treatment 
Cheng [90] Lympho- 
penia 
China Feb 18- 
Apr 10 
100 - 100 21-day mortality: 2 (2%) vs. 10 (10%) (HR 0.19, 95% CI 
0.04 to 0.88) 
Disease progression§§§: 2 (2%) vs. 15 (15%) (difference 
-13%, 95% CI -21.4% to -5.4%) 
Time to clinical improvement (a 1-point reduction on a 
7-category ordinal scale or discharge from hospital): 12 







0.5g/kg/day for 3 days plus 
methylprednisolone (40 mg 








The US May 1- 
Jun 16 
16 - 17 (Among subjects with alveolar-arterial oxygen gradient 
of >200 mmHg at enrollment) 
Initiation of MV within 30 days: 2/14 (14%) vs. 7/12 
(58%) (P = 0.038),  
Length of hospital stay: 11 (range 5–22) vs. 19 (4–30) 
days (P = 0.013) 
Length of ICU stay: 2.5 (range 0–16) vs. 12.5 (1–29) days 
(P = 0.006)  
Difference in PaO2/FiO2 on day 7: +131 (+35 to +330) 
vs.+44.5 (-115 to +157) (P = 0.01). 
Effective 
Vilobelimab (anti-C5a 
antibody IFX-1) 800 mg (day 
1, 2, 4, 8, and 15) vs. standard 
treatment 




15 - 15 28-day mortality: 2 (13%) vs. 4 (27%) (adjusted HR 0.65, 
95% CI 0.10 to 4.14) 
Difference in the change in PaO2/FiO2on day 5 (least 
squares mean): 17% (SD 63) vs. 41% (difference -24%, 
95% CI -58% to 9%, P = 0.15). 
Not effective 
CIGB-325 (anti-CK2) 2.5 
mg/kg (day 1–5) vs. 
standard treatment  
Cruz [93]†† Not 
specified 
Cuba Jun 1- 
Jun 16 
10 - 10 Reduction in the number of pulmonary lesions on the 
chest CT: 5/6 (83%) vs. 3/7 (43%) (Bayesian P 
(difference > 0) = 0.951). 
Time to viral clearance: 11 (SD 8) vs. 12 (SD 6) days (P = 
0.614). 
Effective 
CI: confidence interval; COVID-19: coronavirus disease 2019; CRP: C-reactive protein; CT: computed tomography; DHODH: dihydroorotate dehydrogenase; HR: hazard 
ratio; ICU: intensive care unit; IFN: interferon; IMV: invasive mechanical ventilation; IQR: interquartile range; IU: international unit; MV: mechanical ventilation; NEWS2: 
National Early Warning Score 2; OSCI: ordinal scale for clinical improvement; OR: odds ratio; PCR: polymerase chain reaction; RCT: randomized controlled trial; rhG-CSF: 
Recombinant human granulocyte colony-stimulating factor; RR: relative risk; SD: standard deviation; SE: standard error; SOFA: sequential organ failure assessment; WHO: 
World Health Organization. 
All of the presented studies were conducted in 2020. In the outcome description, the former is the data of the treatment group and the latter is the data of the control group. 
*The United States, Denmark, the United Kingdom, Greece, Germany, South Korea, Mexico, Spain, Japan, and Singapore. †The United States, Italy, Spain, Germany, Hong 
Kong, Singapore, South Korea, and Taiwan. ‡750 mg for participants with a mild or ordinary condition or 1,000 mg for participants with a severe or critical condition. 
§Defined as normalization of body temperature, respiratory rate, oxygen saturation, cough, and absorption of pulmonary infection on chest CT. ¶Resolving from fever to an 
axillary temperature of 36.6°C or below, normalization of SpO2 (> 94% on room air), and disappearance of respiratory symptoms including nasal congestion, cough, sore 
throat, sputum production, and shortness of breath. **The most common adverse event in the treatment group was diarrhea (7/70). ††Preprints from Medrxiv.org. ‡‡Defined 
as development of fever higher than 101 F for more than 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic laboratory parameters 
(absolute lymphocyte count < 1,000 mm3 or raised serum C-reactive protein level), or appearance of infiltrates on chest radiograph during course of treatment. §§In the case 
of azithromycin coadministration, a single 1.0-mg loading dose of colchicine was administered. ¶¶Chloroquine or hydroxychloroquine was administered to 100% and 96% of 
participants in the treatment and the control group, respectively. Azithromycin was administered to 93% and 92% of participants in the treatment and the control group, 
respectively. ***Defined as a Borg score > 3, improved dyspnea, stopped fever for 72 hours, SO2 > 93%, tolerated oral regimen, normal urinary output, and reduced C-reactive 
protein level without any side effects. †††The dosage was determined according to age, body weight, and creatinine clearance. ‡‡‡The deferred treatment group received 
convalescent plasma only when a PaO2/FiO2 < 200 criterion was met during hospitalization or when the patient still required hospitalization for symptomatic COVID-19 
more than 7 days after enrollment. §§§Progression to acute respiratory distress syndrome, sepsis, or septic shock. 
 
Table 4. Summary of meta-analyses evaluating therapeutics for COVID-19 
Comparisons  First author No. of studies No. of participants Type of 
metrics 
Model Summary effect 
(95% CI) 
P I2 (P) Publication 
bias 
Conclusion 
Antiviral agents             
Remdesivir             




RR Random 0.74 (0.40 to 1.37) NA 58% (0.12) NA Not effective 
Clinical 
recovery 




RR Fixed 1.17 (1.07 to 1.29) NA 0% (0.70) NA Effective 
Clinical 
improvement*  
(5 vs. 10-days of 
treatment) 




OR Random 1.33 (1.01 to 1.76) NA NA NA Favors 5-day 
treatment 




RR Fixed 0.91 (0.79 to 1.05) NA 7% (0.30) NA Inconclusive 
Serious adverse 
events 




RR Random 0.77 (0.63 to 0.94) 0.01 0.0% (0.66) NA Inconclusive 
Favipiravir             
Clinical 
improvement  
by day 14 
Shrestha [187] 2 [31, 188] 1 73 (41)/ 
84 (49) 
49 (21)/75 (30) RR Fixed 1.29 (1.08 to 1.54) 0.005 16% (0.30) NA Effective 
 Shrestha [187] 2 [31, 188] 0 41 (41)/ 
49 (49) 
21 (21)/30 (30) RR Fixed 1.12 (0.87 to 1.44) 0.37 0% (0.98) NA Not effective 
Viral clearance 
by day 14 
Shrestha [187] 2 [31, 188] 1 77 (44)/ 
84 (49) 
61 (28)/75 (30) RR Random 1.06 (0.84 to 1.33) 0.65 67% (0.05) NA Inconclusive 
 Shrestha [187] 2 [31, 188] 0 44 (44)/ 
49 (49) 
28 (28)/30 (30) RR Random 0.95 (0.74 to 1.22) 0.67 41% (0.19) NA Inconclusive 
Umifenovir             
Clinical 
recovery 
Misra [22] 1 [34] 1 51 (32)/ 
69 (35) 
40 (13)/65 (17) RR Fixed 1.08 (0.85 to 1.38) NA 0% (0.42) N Not effective 





Comparisons  First author No. of studies No. of participants Type of 
metrics 
Model Summary effect 
(95% CI) 
P I2 (P) Publication 
bias 
Conclusion 
Viral clearance  
(on day 14) 




RR Random 1.27 (1.04 to 1.55) 0.02 63% (0.03) NA Possible 
effect 
Adverse events Misra [22] 1 [34] 1 8 (5)/69 (35) 4 (0)/65 (17) RR Fixed 1.80 (0.52 to 6.19) NA 10% (0.29) N Inconclusive 
Lopinavir/ritonavir            
Clinical 
recovery 




RR Fixed 1.08 (0.94 to 1.24) NA 0% (0.70) N Not effective 




RR Fixed 0.90 (0.76 to 1.07) 0.225 33.9% 
(0.220) 
N Inconclusive 
 Liu [43] 2 [34, 40]  0 48 (48)/ 
80 (80) 
45 (45)/78 (78) RR Random 0.99 (0.76 to 1.29) 0.93 0% (0.74) NA Inconclusive 








Zhong [189] 1 [40] 1 4 (2)/147 (95) 7 (7)/147 (99) RR Random 0.86 (0.66 to 11.97) NA 61% 
(0.110) 
NA Inconclusive 
Hydroxychloroquine            
28-day 
mortality 
Elsawah [190] 2 [179, 180] 0 0 (0)/ 
239 (239) 
0 (0) 264 (264) RD Fixed 0.00 (-0.01 to 0.01) 1.00 0% (1.00) NA Not effective 
Mortality Yang [191] 1 [192] 4 91 (0)/ 
451 (15) 
284 (0)/930 (15) OR Random 1.23 (0.38 to 3.97) 0.73 88% 
(<0.0001) 
N Not effective 
 Das [193] 0 8 268 (0)/ 
2009 (0) 
533 (0)/3671 (0) OR Random 0.87 (0.46 to 1.64) 0.66 92% 
(<0.00001) 




0 4 452 (0)/ 
2111 (0) 





 Zang [195] 0 3 63 (0)/311 (0) 27 (0)/268 (0) RR Fixed 1.92 (1.26 to 2.93) 0.003 0% (0.508) NA Harmful 
Deterioration† Yang [191] 3 [55, 180, 192] 3 48 (2)/ 
494 (116) 
29 (4)/540 (126) OR Random 2.46 (0.42 to 14.45) 0.32 69% 
(0.007) 
N Not effective 
 Liu [43] 3 [55, 180, 192]  0 2 (2)/ 
115 (115) 
4 (4)/125 (125) RR Random 0.96 (0.10 to 9.66) 0.98 41% (0.8) NA Not effective 




RR Random 1.05 (0.61 to 1.81) NA 62.5% 
(0.031) 





Elsawah [190] 2 [55, 192] 2 11 (1)/89 (46) 6 (4)/83 (46) RD Fixed 0.06 (-0.03 to 0.15) 0.18 76% 
(0.006) 
NA Not effective 
Clinical 
progression 
within 28 days‡ 




RD Fixed -0.00 (-0.04 to 0.04) 0.86 0% (0.33) NA Not effective 
Death or 
invasive MV 
Putman [196] 0 2 166 (0)/ 
895 (0) 
83 (0)/654 (0) HR Random 1.03 (0.82 to 1.29) 0.81 0% (0.75) NA Not effective 
Death or 
deterioration† 
Sarma [197] 2 [55, 192] 1 5 (1)/66 (46) 4 (4)/62 (46) OR Random 1.37 (0.09 to 21.97) 0.82 59% (0.09) NA Not effective 
Death or 
deterioration†  
(≤ 400 mg/day) 
Yang [191] 2 [55, 192] 2 64 (1)/365 
(46) 
270 (4)/787 (46) OR Random 0.64 (0.14 to 2.81) 0.55 84% 
(0.0002) 
N Not effective 
Death or 
deterioration† 
(> 400 mg/day) 
Yang [191] 1 [180] 1 5 (1)/90 (70) 0 (0)/96 (80) OR Fixed 6.17 (0.71 to 53.47) 0.10 0% (0.67) N Not effective 
Clinical 
recovery 




RR Random 0.93 (0.84 to 1.04) NA 74% 
(<0.01) 
Y Not effective 
 Talaie [198] 2 [55, 180] 0 70 (70)/ 
106 (106) 
67 (67 )/ 
106 (106) 
RR Random 1.04 (0.85 to 1.28) NA 79.3% 
(0.028) 
NA Not effective 
Radiological 
improvement 
Ullah [199] 2 [55, 192] 1 40 (30)/ 
56 (46) 
33 (24)/58 (46) OR Random 1.98 (0.47 to 8.36) 0.36 54% (0.11) N Not effective 
Radiological 
progression 
Sarma [197] 2 [55, 192] 0 7 (7)/46 (46) 16 (16)/46 (46) OR Random 0.31 (0.11 to 0.90) 0.03 16% (0.27) NA Not effective 
Viral clearance Singh [200] 2 [180, 192] 1 80 (72)/ 
99 (85) 
81 (79)/111 (95) RR Random 1.05 (0.79 to 1.38) 0.744 62% (0.07) Y Inconclusive 
 Liu [43] 2 [180, 192] 0 77 (77)/ 
90 (90) 
80 (80)/90 (90) RR Random 0.98 (0.89 to 1.07) 0.65 0% (0.54) NA Inconclusive 
 Elavarasi [201] 0 3 217 (0)/ 
240 (0) 






















Elsawah [190] 3 [179, 180, 192] 0 157 (157)/ 
254 (254) 








Elsawah [190] 3 [55, 179, 180] 0 65 (65)/ 
270 (270) 








Ullah [199] 2 [180, 192] 1 2 (2)/ 
111 (101) 
2 (0)/123 (111) OR Random 1.26 (0.20 to 7.98) 0.81 0% (0.37) N Inconclusive 
Adverse events 
(cardiac) 
Elsawah [190] 2 [179, 180] 0 3 (3)/ 
239 (239) 
0 (0)/264 (264) RD Fixed 0.01 (-0.01 to 0.03) 0.16 84% (0.01) NA Inconclusive 
Hydroxychloroquine plus azithromycin           





Comparisons  First author No. of studies No. of participants Type of 
metrics 
Model Summary effect 
(95% CI) 
P I2 (P) Publication 
bias 
Conclusion 
Mortality Das [193] 0 4 NA (0)/ 
1145 (0) 
NA (0)/1165 (0) OR Random 2.84 (2.19 to 3.69) <0.00
001 
0% (0.43) Y Harmful 
 Yang [191] 0 3 214 (0)/ 
854 (0) 
46 (0)/395 (0) OR Fixed 2.34 (1.63 to 3.36) <0.00
001 
0% (0.85) N Harmful 
Deterioration† Yang [191] 0 3 101 (0)/ 
840 (0) 




N Not effective 
 Wang [42] 0 2 115 (0)/ 
328 (0) 
833 (0)/3969 (0) RR Random 0.93 (0.17 to 5.09) NA 94.2% 
(<0.001) 
N Not effective 
Corticosteroids             
Mortality Lu [67] 0 4 94 (0)/329 (0) 58 (0)/408 (0) RR Random 2.00 (0.69 to 5.75) NA 90% 
(<0.001) 





Ye [68] 0 2 NA (0)/ 
227 (0) 
NA (0)/104 (0) HR Random 2.30 (1.00 to 5.29) NA 0% (0.768) NA Not effective 
Time to viral 
clearance 
Sarkar [69] 0 2 82 69 MD Random 1.42 (-0.52 to 3.37) 0.15 0% (0.52) NA Not effective 
Renin-angiotensin-aldosterone system inhibitors for patients with hypertension        
Mortality 
(ACEI) 
Pranata [73] 0 3 29 (0)/110 (0) 87 (0)/326 (0) OR Random 0.68 (0.39 to 1.17) 0.16 0% (0.62) Y Not effective 
Mortality (ARB) Pranata [73] 0 3 29 (0)/158 (0) 87 (0)/326 (0) OR Random 0.51 (0.29 to 0.90) 0.02 22% (0.28) Y Effective 
Mortality  
(ACEI or ARB) 
Flacco [74]  0 4 NA (0)/ 
921 (0) 
NA (0)/1491 (0) OR Random 0.88 (0.68 to 1.14) 0.33 24% (0.27) N Not effective 
Anticoagulants             
Mortality Lu [76] 0 5 536 (0 )/ 
2886 (0) 
947 (0)/5647 (0) RR Random 0.86 (0.69 to 1.09) 0.218 47.4% 
(0.107) 







0 2 50 (0)/126 (0) 115 (0)/368 (0) RR Random 1.09 (0.84 to 1.42) NA 0% (0.537) NA Not effective 
Convalescent plasma            
Mortality Talaie [198] 1 [87] 2 10 (8)/82 (52) 21 (12)/81 (51) RR Random (0.26 to 1.03) NA 0% (0.484) N Not effective 
Clinical 
improvement 
Talaie [198] 1 [87] 2 46 (27)/ 
82 (52) 
32 (22)/81 (51) RR Random 1.41 (1.01 to 1.98) NA 66.6% 
(0.050) 
Y Effective 
Viral clearance Sarkar [202] 1 [87] 2 54 (41)/ 
68 (52) 




0% (0.40) Y Possible 
effect 
Tocilizumab             
Mortality Lan [203]§ 0 7 39 (0)/241 (0) 85 (0)/352 (0) RR Random 0.61 (0.31 to 1.22) 0.16 68% 
(0.005) 




Malgie [94] 0 2 7 (0)/94 (0) 22 (0)/56 (0) RD Random -0.31 (-0.57 to 
-0.05) 
NA NA Y Effective 
ICU admission 
and initiation of 
MV 
Lan [203]§ 0 5 47 (0)/134 (0) 44 (0)/279 (0) RR Random 1.51 (0.33 to 6.78) 0.59 86% 
(<0.00001) 
NA Not effective 
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARDS: acute respiratory distress syndrome; CI: confidence interval; CNS: central 
nervous system; COVID-19: coronavirus disease 2019; ECG: electrocardiogram; HR: hazard ratio; ICU: intensive care unit; MD: mean difference; MV: mechanical ventilation; 
NA: not applicable; OR: odds ratio; RCT: randomized controlled trial; RD: risk difference; RR: relative risk. 
The RCTs included in the meta-analyses of this table were also included in our target RCTs and are presented in Table 3, except an RCT [25] with no peer-reviewed or 
preprint report released, an RCT [192] published in Chinese, and an RCT [188] in which a statistical analysis was not conducted. *A 2-point reduction on a 7-category ordinal 
scale. †Progression to severe COVID-19. ‡An increase in severity compared to the baseline severity. §One participant in the treatment arm of one included study was 




In two human non-RCTs on SARS, the treatment 
group performed better with respect to the overall 
mortality rate or the incidence of ARDS [36, 37]. An 
ongoing RCT on MERS involved a combination of 
lopinavir/ritonavir and IFN-β [19], which has been 
shown to be effective in two in vivo studies on MERS 
[38, 39] (Table 1). In an RCT on COVID-19, treatment 
with lopinavir/ritonavir was not associated with a 
mortality rate reduction at day 28 (treatment group 
19.2% vs. control group 25.0%; difference, -5.8%; 95% 
CI -17.3% to 5.7%) [40]. In the aforementioned RCT on 
COVID-19 comparing a combination of lopinavir/ 
ritonavir and umifenovir with standard treatment 
[34], and in another RCT on COVID-19 comparing 
“lopinavir/ritonavir plus IFN-α with or without 
ribavirin” with “ribavirin plus IFN-α” [41], treatment 
with lopinavir/ritonavir did not show superior 
outcomes in terms of clinical deterioration or viral 
clearance (Table 3). In meta-analyses on COVID-19 
involving two of these RCTs [34, 40], treatment with 
lopinavir/ritonavir was not associated with clinical 
recovery or viral clearance [22, 42, 43] (Table 4). 
Ribavirin 
Ribavirin has been investigated in previous 
studies on SARS and MERS, but the results were not 
consistent (Table 1). Although one RCT for a 
combination therapy of ribavirin and lopinavir/ 
ritonavir in SARS was registered [18], it seems 
unlikely that this trial can be finished, as SARS has not 





occurred for a while. In two in vitro studies on 
COVID-19, ribavirin did not show therapeutic effects 
[29, 30] (Table S1). In the aforementioned RCT on 
COVID-19, comparing “ribavirin plus interferon 
IFN-α with or without lopinavir/ritonavir” with 
“lopinavir/ritonavir plus IFN-α”, treatment with 
ribavirin did not show better outcome in terms of the 
clinical deterioration or viral clearance [41]. In another 
RCT on COVID-19, a combination of ribavirin and 
IFN-β1b was evaluated: In the treatment group, the 
time taken to achieve a National Early Warning Score 
2 (NEWS2) (4 [IQR 3–8] vs. 8 [7–9] days; HR 3.92, 95% 
CI 1.66 to 9.23) or sequential organ failure assessment 
(SOFA) score of zero (3.0 [IQR 1.0–8.0] vs. 8.0 [6.5–9.0] 
days; HR 1.89, 95% CI 1.03 to 3.49), the hospitalization 
period (9.0 [IQR 7.0–13.0] vs. 14.5 [9.3–16.0] days; HR 
2.72, 95% CI 1.2 to 6.13), and time to viral clearance (7 
[IQR 5–11] vs. 12 [8–15] days; HR 4.37, 95% CI 1.86 to 
10.24, P = 0.001) were shorter than those of the control 
group [44] (Table 3). 
Other antiviral agents 
In a small-scale RCT on mild to moderate 
COVID-19, azvudine (FNC) treatment showed better 
outcome with respect to radiological improvement (P 
= 0.0401) and viral clearance (P = 0.0011) [45]. In the 
other RCTs on COVID-19, triazavirin [46] or a 
combination of darunavir and cobicistat [47] did not 
show therapeutic effects (Table 3). Nelfinavir showed 
therapeutic effects in one [48] out of two in vitro 
studies on SARS (Table 1) and in an in vitro study on 
COVID-19 [49] (Table 2). 
4-Aminoquinoline 
In a study on SARS, chloroquine showed an 
effect in vitro but not in vivo, and these results were 
similar for amodiaquine [50]. The results of two in 
vitro studies of chloroquine for MERS conflicted with 
each other [51, 52]. Multiple in vitro studies on 
COVID-19 reported effects of chloroquine [29, 53, 54] 
and hydroxychloroquine [53, 54]. In a preprint RCT 
on COVID-19, hydroxychloroquine was administered 
with a daily dosage of 400 mg for five consecutive 
days and the treatment group showed higher rates of 
improvement in chest computed tomography (CT) 
scans on day 6 (25 out of 31 [81%] vs. 17 out of 31 
[55%], P = 0.0476) and shorter duration of fever (2.2 
[standard deviation (SD) 0.4] vs. 3.2 [1.3] days, P = 
0.0008) [55]. In another preprint RCT conducted in 
Pakistan enrolling 500 patients with mild COVID-19, 
the proportion of patients with negative viral PCR 
results within seven days was higher in the 
hydroxychloroquine-treated group (182 out of 349 
[52%] vs. 54 out of 151 [36%], P = 0.001) [56]. However, 
in the other four RCTs and one preprint RCT on 
COVID-19 involving a total of 815 participants, 
treatment with hydroxychloroquine did not show 
better outcome compared to standard treatment 
(Table 3). In 15 meta-analyses on COVID-19, 
treatment with hydroxychloroquine showed no 
therapeutic effect and higher risk for adverse events. 
A combination of hydroxychloroquine and 
azithromycin was also evaluated in three 
meta-analyses on non-RCTs for COVID-19 and 
showed a harmful effect (Table 4). 
Azithromycin 
In an RCT on azithromycin for COVID-19, the 
hospitalization period of the treatment group was 
shorter than that of the control group (4.6 [SD 2.6] vs. 
6.0 [SD 3.2] days, P = 0.02) [57]. However, in another 
RCT on azithromycin involving 397 patients with 
severe COVID-19, azithromycin did not show any 
therapeutic effect [58] (Table 3). 
Corticosteroids 
In an RCT targeting SARS, early administration 
(within 7 days) of corticosteroids was associated with 
higher subsequent plasma viral concentrations in the 
second and third week of the illness [59]. However, in 
this study, the severity of disease did not differ 
between the early corticosteroid treatment group and 
the control group. In addition, there was no 
significant difference in the median time for the virus 
to become undetectable in plasma between the early 
corticosteroid treatment group and the control group 
(12 vs. 8 days, P = 0.106). Therefore, it is difficult to 
conclude that this study supports the risk of 
corticosteroid treatment. A non-RCT on SARS 
demonstrated that corticosteroid therapy was 
associated with higher risk for either ICU admission 
or mortality (OR 20.7, 95% CI 1.3-338.0) [60]. This 
study had several important limitations, including the 
following: (1) the 95% CI was extremely asymmetric; 
(2) there was no difference in mortality between the 
steroid-treated and non-treated groups in a simple 
univariate analysis, but corticosteroid therapy was 
included in the logistic regression; (3) the 
steroid-treated group had a more severe disease 
course, which indicates a case of confounding by 
indication; and (4) not all of the potential variables 
were adjusted, which could influence the results. 
In a non-RCT on MERS, corticosteroid therapy 
was not associated with 90-day mortality but 
associated with delay in viral clearance (adjusted HR 
0.35, 95% CI 0.17-0.72) under a marginal structural 
model [61]. However, this study also shared many of 
the shortcomings mentioned above such as 
corticosteroids being used for patients with severe 
conditions, which can introduce severe levels of bias. 





In this retrospective study, at least a propensity-score 
matching analysis should have been considered. 
Three non-RCTs of corticosteroid use in SARS 
showed effectiveness of high dose [62-64]. One 
non-RCT on SARS demonstrated that the survival 
outcome of the group receiving methylprednisolone 
was superior compared to the group not receiving 
corticosteroids as well as the group receiving 
hydrocortisone or pulse therapy [65]. In an RCT on 
methylprednisolone treatment for severe COVID-19, 
the treatment group showed a lower mortality rate (2 
out of 34 [6%] vs. 12 out of 28 [43%], P < 0.001) and a 
higher rate of clinical improvement (32 out of 34 [94%] 
vs. 16 out of 28 [57%], P = 0.001) compared to the 
control group [66]. Meta-analyses on corticosteroid 
therapy for COVID-19 included only non-RCTs and 
did not demonstrate any significant therapeutic effect 
of corticosteroids [67-69] (Table 4). 
Colchicine 
In two RCTs on COVID-19, colchicine showed 
effects in major outcomes. Among them, in a Greek 
RCT, the treatment group had a higher cumulative 
event-free 10-day survival rate (97% vs. 83%, P = 0.03), 
a longer event-free survival period (21 [SD 0.31] vs. 19 
[0.83] days, P = 0.03), and a lower incidence of 
deterioration within three weeks (2% vs. 14%; OR 0.11, 
95% CI 0.01 to 0.96; P = 0.046) [70]. In another preprint 
RCT conducted in Brazil, the treatment group had a 
shorter duration of supplemental oxygen therapy (3.0 
[IQR 1.5–6.5] vs. 7.0 [3.0–8.5] days, P = 0.02), a lower 
proportion of participants requiring supplemental 
oxygen on day 7 (6% vs. 39%, P = 0.01), a shorter 
length of hospital stay (6.0 [IQR 4.0–8.5] vs. 8.5 [5.5–
11.0] days, P = 0.03), and lower rate of hospitalization 
(53% vs. 78% on day 5; 6% vs. 17% on day 10; P = 0.01) 
[71]. 
ACEI or ARB 
In a preprint RCT on 82 participants with 
COVID-19, telmisartan was administered to the 
treatment group with a daily dosage of 160 mg for 14 
consecutive days. The treatment group had a shorter 
duration of hospital stay (9 vs. 15 days, P = 0.0124) and 
the HR for hospital discharge was 2.02 (95% CI 1.14 to 
3.59) [72] (Table 3). In a meta-analysis that included 
three non-RCTs on COVID-19 with hypertension, 
ARB showed a survival benefit (OR for mortality 0.51, 
95% CI 0.29 to 0.90, P = 0.02; I2 = 22%, n = 484) 
although there was a publication bias [73]. In another 
meta-analysis that included non-RCTs on COVID-19, 
the effect of ACEI or ARB therapy on COVID-19 with 
hypertension was not significant [74] (Table 4). 
Anticoagulants 
In a small-scale RCT for severe COVID-19, 
therapeutic anticoagulant therapy with enoxaparin 
and prophylactic anticoagulant therapy with 
enoxaparin or unfractionated heparin were 
compared. A greater proportion of participants in the 
therapeutic anticoagulant group were able to be 
weaned from MV successfully compared to the 
prophylactic anticoagulant group (8 out of 10 [80%] 
vs. 3 out of 10 [30%]; HR 4.0, 95% CI 1.04 to 15.05; P = 
0.031) [75] (Table 3). In two meta-analyses including 
non-RCTs on COVID-19, anticoagulant therapy did 
not show a therapeutic effect [76, 77] (Table 4). 
Calcifediol 
Calcifediol was studied in one RCT on 
COVID-19. In this RCT, a lower proportion of 
participants in the treatment group were admitted to 
the ICU compared to the control group (1 out of 50 
[2%] vs. 13 out of 26 [50%]; adjusted OR 0.03, 95% CI 
0.003 to 0.25) [78] (Table 3). 
CM4620-IE (AuxoraTM, calcium release- 
activated calcium channel inhibitor) 
In an RCT on severe or critical COVID-19, the 
proportion of patients who received invasive MV or 
died was lower in the Auxora-treated group than the 
control group (3 out of 17 [18%] vs. 5 out of 9 [6%]; HR 
0.23, 95% CI 0.05 to 0.96; P < 0.05) and the mean 
difference in the 8-point ordinal scale was statistically 
significant on day 6 and day 9 to 12 (P < 0.05) [79] 
(Table 3). 
Janus-associated kinase inhibitors 
In an in vitro study on MERS, baricitinib showed 
an effect [80] (Table 1). Ruxolitinib was evaluated in 
an RCT on severe COVID-19 and showed higher rates 
of improvement on chest CT scans on day 14 (18 out 
of 20 [90%] vs. 13 out of 21 [62%], P = 0.0495) and 
shorter time to lymphocyte recovery (5 [IQR 2–7] vs. 8 
[2–11] days, P = 0.033) [81] (Table 3). 
Leflunomide (dihydroorotate dehydrogenase 
inhibitor) 
In a small-sized RCT on moderate COVID-19, 
the duration of viral shedding was shorter in the 
leflunomide-treated group compared with the control 
group (5 vs. 11 days, P = 0.046) [82] (Table 3). 
Immunotherapy 
Interferon 
Both IFN-α and IFN-β showed numerous 
positive results in non-human studies on SARS or 
MERS. However, a meta-analysis on MERS did not 
show that the interferon therapy was effective [14]. 
For COVID-19, five RCTs on interferon have been 
published to date. In an RCT evaluating IFN-β1a 





treatment, the rate of hospital discharge was higher 
(67% vs. 44%; OR 2.5, 95% CI 1.05 to 6.37) and the 
28-day mortality rate was lower (19% vs. 44%, P = 
0.015) in the treatment group compared to the control 
group [83]. In the aforementioned RCT evaluating a 
combination of IFN-β1b and ribavirin, the treatment 
group performed better [44]. In another RCT on 
severe COVID-19, treatment with IFN-β1b showed 
better outcomes in terms of discharge from the 
hospital and admission to the ICU compared to 
standard treatment [84]. Inhaled IFN-κ plus TFF2 
therapy was investigated in one RCT on moderate 
COVID-19. In this study, the chest CT findings of 
participants in the treatment group improved within a 
shorter time compared to the control group (6.2 [95% 
CI 5.1–7.3] vs. 8.8 [95% CI 7.6-10.0] days, P = 0.002) 
[85]. In an RCT evaluating Novaferon therapy, the 
group receiving the combination of Novaferon and 
lopinavir/ritonavir had a higher rate of viral 
clearance on day 6 (18 out of 30 [60%] vs. 7 out of 29 
[24%], P = 0.0053) and a shorter median time to 
negative results of virus PCR (6 vs. 9 days, P = 0.036) 
compared with the group receiving lopinavir/ 
ritonavir [86] (Table 3). 
Convalescent plasma 
A meta-analysis of convalescent plasma therapy 
in patients with SARS demonstrated that the absolute 
reduction in the risk of mortality was 7% and 23% in 
two studies, and the case fatality rate from four non- 
comparative studies varied from 0% to 12.5% [12]. In 
an RCT for severe or life-threatening COVID-19, the 
proportion of participants who recovered clinically 
within 28 days was higher in the treatment than in the 
control group in cases with severe COVID-19 (21 out 
of 23 [91%] vs. 15 out of 22 [28%]; HR 2.15, 95% CI 1.07 
to 4.32) [87]. Four preprint RCTs on COVID-19 have 
investigated the effect of convalescent plasma. In one 
of these RCTs, a lower proportion of participants in 
the treatment group compared to the control group 
either required MV or died (0 out of 38 [0%] vs. 6 out 
of 43 [14%], P = 0.03) [88]. Another RCT on moderate 
COVID-19 involving more participants (n = 464) did 
not show the therapeutic effect of convalescent 
plasma [89] (Table 3). 
Recombinant human granulocyte colony-stimulating 
factor (rhG-CSF) 
In an RCT for COVID-19 with lymphopenia, 
participants in the treatment group who received 
rhG-CSF showed lower rates of 21-day mortality (2 
out of 100 [2%] vs. 10 out of 100 [10%]; HR 0.19, 95% 
CI 0.04 to 0.88) and disease progression (2 out of 100 
[2%] vs. 15 out of 100 [15%]; mean difference -13%, 
95% CI -21.4% to -5.4%) [90] (Table 3). 
Intravenous immunoglobulin 
In a preprint RCT on COVID-19, the 3-day 
course of intravenous immunoglobulin therapy 
showed a lower rate of MV within 30 days (2 out of 14 
[14%] vs. 7 out of 12 [58%], P = 0.038), shorter hospital 
stay (11 [range 5–22] vs. 19 [4–30] days, P = 0.013) or 
ICU stay (2.5 [range 0–16] vs. 12.5 [1–29] days, P = 
0.006), and improvement in PaO2/FiO2 ratio on day 7 
(difference +131 [+35 to +330] vs. +44.5 [-115 to +157], 
P = 0.01) among the participants who had an 
alveolar-arterial oxygen gradient greater than 200 
mmHg at enrollment [91] (Table 3). 
Other immunotherapies 
In a small-scale RCT on severe COVID-19, 
vilobelimab (anti-C5a antibody IFX-1) treatment did 
not show a therapeutic effect [92]. In a small-scale 
RCT on CIGB (anti-CK2) for COVID-19, there was a 
reduction in the number of pulmonary lesions on 
chest CT in a greater proportion of participants in the 
treatment group compared to the control group (5 out 
of 6 [83%] vs.3 out of 7 [43%]; Bayesian P (difference > 
0) = 0.951) [93]. Multiple observational clinical studies 
on tocilizumab (anti-interleukin [IL] -6 receptor 
antibody) for COVID-19 were investigated in two 
meta-analyses. Among them, a subgroup analysis, in 
which lopinavir and ritonavir were and 
corticosteroids were not administered to all 
participants, showed a lower mortality rate in the 
tocilizmub treatment group (risk difference -0.31, 95% 
CI -0.57 to -0.05) [94] (Table 4).  
Discussion 
We summarized the results of studies conducted 
on SARS, MERS, and COVID-19 to date. 
Unfortunately, completed RCTs for the treatment of 
SARS and MERS were scarce. We assumed this was 
because SARS was a relatively short-lived epidemic 
that has not occurred since 2004, and the number of 
patients with MERS might have been insufficient for 
recruitment. In the case of COVID-19, numerous RCTs 
have been registered, and research results have been 
consistently reported despite the global pandemic and 
medical crisis. 
It was difficult to find an optimal therapeutic 
agent that consistently resulted in positive outcomes 
across SARS, MERS, and COVID-19. One of the 
possible reasons of this is that there might not be a 
universal “cure” to these viral diseases given the 
differences in presentation forms. Reduction of the 
viral load may not be the only aim when attempting 
to cure the disease. The subtle differences between 
these three coronaviruses, as well as the lack of 
objective information from clinical experiences of the 
preceding SARS and MERS epidemics, may also be 






Synthesizing studies on COVID-19 highlighted 
two main goals in the treatment of COVID-19: (1) 
effective elimination of the virus and (2) immune 
regulation to interfere with the mechanisms of 
cytokine storm. Therefore, extensive further research 
on various antiviral agents and immunomodulators is 
expected to continue for a while. 
Among the antiviral agents presented in our 
study, remdesivir has consistently shown potent 
effects in non-human studies on SARS, MERS, and 
COVID-19. Remdesivir is a novel broad-spectrum 
antiviral agent. When remdesivir is administered into 
the human body, it is metabolized to an active 
metabolite, which is an adenosine nucleoside 
triphosphate analogue. It interferes with the action of 
viral RNA polymerase and evades proofreading by 
viral exoribonuclease (ExoN), which interferes with 
RNA replication of the virus [95]. This agent showed 
an effect in the largest of the four RCTs on COVID-19 
that included 1,062 participants. In this RCT, the 
14-day mortality rate was significantly lower in the 
subgroup with requirement of only supplemental 
oxygen not MV, suggesting that there is a patient 
population with a certain level of severity of 
COVID-19 that could benefit from remdesivir 
treatment [20]. Therefore, it seems necessary to 
preferentially administer remdesivir to this specific 
group of patients. In addition, it should be considered 
in the clinical application that the outcome of 5-day 
regimen treatment was better than that of the 10-day 
regimen in two RCTs [23, 24]. On October 22, 2020, the 
Food and Drug Administration (FDA) approved the 
use of remdesivir for treatment of COVID-19 
requiring hospitalization. 
A combination of sofosbuvir and daclatasvir 
consistently showed an effect on the major outcomes 
in two RCTs on COVID-19. Sofosbuvir is a nucleotide 
analog targeting the hepatitis C virus (HCV) 
polymerase, NS5B. This agent is capable of inhibition 
of positive-strand RNA viruses like coronavirus. 
Daclatasvir is an HCV NS5A antagonist and is known 
to penetrate lung tissue effectively. Daclatasvir has 
been shown to inhibit the production of SARS-CoV-2 
particles in an in vitro study [96]. Those two RCTs 
investigating the combination of sofosbuvir and 
daclatasvir had limitations because they included a 
small number of participants and did not show 
significant results for mortality. Therefore, a large- 
scale RCT on this treatment is still required. 
Favipiravir is an antiviral agent that is drawing 
attention as a treatment option for COVID-19. The 
active metabolite of favipiravir competes with purine 
nucleosides and incorporates into viral RNA to 
interfere with viral replication, potentially inhibiting 
the RNA dependent RNA polymerase (RdRp) of RNA 
viruses [97]. Considering that favipiravir showed an 
effect in terms of viral clearance in an RCT on 
COVID-19 [31], a large-scale, well-designed RCT is 
further required. A number of RCTs on favipiravir are 
now underway. 
Umifenovir is a small indole-derivative molecule 
with broad-spectrum antiviral property, and it has 
been approved in Russia and China for the 
prophylaxis and treatment of influenza. It inhibits the 
virus from fusion to the target cell membrane and 
blocks viral entry into the cell [98]. Since a 
meta-analysis including one RCT and multiple 
observational studies on umifenovir for COVID-19 
demonstrated significant results for viral clearance 
[35], well-designed RCTs on umifenovir still needs to 
be conducted. 
Lopinavir/ritonavir combination therapy seems 
to have more therapeutic effect than monotherapy of 
each drug. As protease inhibitors, lopinavir and 
ritonavir can inhibit the action of 3CLpro, coronavirus 
main protease, and interfere with the process of viral 
replication and release [99]. However, the clinical 
results of this combination therapy for COVID-19 
were not meeting expectations compared to those of 
SARS and MERS. In a first RCT on lopinavir/ritonavir 
for COVID-19, the outcomes of the treatment group 
and the control group did not show a significant 
difference, but the 28-day mortality of the treatment 
group were slightly lower [40]; and in two other RCTs 
and four meta-analyses on COVID-19, treatment with 
lopinavir/ritonavir did not show an effect. 
Azvudine (FNC) is a novel nucleoside reverse 
transcriptase inhibitor targeting HCV and has been 
investigated for treatment of human immuno-
deficiency virus (HIV) [100]. Azvudine showed 
promising effects in terms of radiological 
improvement and viral clearance in a small-scale RCT 
for mild to moderate COVID-19 [45]. RCTs involving 
more participants are required. 
The 4-aminoquinoline is mainly used as an 
anti-malaria agent, and hydroxychloroquine, one of 
its derivatives, is also used as an immunomodulatory 
agent. Chloroquine and hydroxychloroquine inhibits 
the pH-dependent steps of viral replication by 
increasing the pH of phagolysosome [101]. The study 
on SARS showed in vitro but not in vivo effects of 
chloroquine and amodiaquine [50], and combination 
therapy with other drugs that inhibit viral replication 
may be necessary. In our study, we investigated seven 
RCTs and 15 meta-analyses on hydroxychloroquine 
for COVID-19 and only one preprint small-scale RCT 
demonstrated an effect of hydroxychloroquine on the 
major outcomes [55]. The survival benefit of 
hydroxychloroquine treatment has not been 





demonstrated in any of these seven RCTs. The results 
of the latest large-scale RCT [102], which was 
excluded from our study since it included patients 
with suspected COVID-19, as well as multiple 
meta-analyses were consistent with this. In addition, 
the risk for adverse events of hydroxychloroquine 
treatment was higher compared to standard treatment 
according to the results of meta-analyses. Therefore, 
hydroxychloroquine seems to have no value as a 
therapeutic agent for COVID-19. 
It is worth noting that an RCT for chloroquine, 
excluded due to involvement of patients with 
suspected COVID-19 [103], suggested the risk of 
high-dose chloroquine treatment and this risk was 
associated with prolongation of the QT interval. 
Similarly, hydroxychloroquine treatment was also 
related to QT prolongation [104, 105]. Therefore, it is 
expected that if careful monitoring for prolongation of 
the QT interval is not accompanied, chloroquine or 
hydroxychloroquine treatment can be rather harmful. 
In this regard, the World Health Organization (WHO) 
recently decided to implement the temporary pause of 
the hydroxychloroquine arm within the Solidarity 
Trial, a large-scale study on four untested treatments 
for COVID-19 [106]. The FDA also withdrew 
emergency use authorization for chloroquine and 
hydroxychloroquine [107]. 
For severe inflammatory diseases caused by 
infection, corticosteroid therapy is a double-edged 
sword. Although a number of corticosteroid therapies 
have already been used in SARS, MERS, and 
COVID-19, these results are controversial and difficult 
to interpret. It is noteworthy that the study of SARS 
showed a difference in outcomes depending on the 
type or dosage of steroids [65]. In most observational 
studies on COVID-19, corticosteroid therapy was 
mainly administered in a group with severe clinical 
conditions according to the prevailing guidelines [7]. 
Because of this strong tendency, patients with 
COVID-19 who received corticosteroids had poor 
treatment outcomes, and objective validation of 
corticosteroid treatment has been highly required. 
In response to this request, the results of the first 
RCT to investigate corticosteroid therapy in 
COVID-19 were recently reported, although it was 
excluded from our study because participants with 
negative SARS-CoV-2 PCR results were included. 
This RCT involved 2,104 and 4,321 participants in the 
treatment and control group, respectively. The 28-day 
mortality rate of the group receiving 10 days of 
dexamethasone treatment was lower than that of the 
control group (482 out of 2,104 [23%] vs. 1,110 out of 
4,321 [26%]; RR 0.83, 95% CI 0.75 to 0.93; P < 0.001), 
and this trend was stronger among the subgroup with 
higher severity of COVID-19: (1) 95 out of 324 patients 
(29%) in the treatment group and 283 out of 683 
patients (41%) in the control group among patients 
requiring invasive MV (RR 0.64, 95% CI 0.51 to 0.81) 
(2) 298 out of 1,279 patients (23%) in the treatment 
group and 68 out of 2,604 patients (26%) in the control 
group among patients requiring only oxygen 
supplement (RR 0.82, 95% CI 0.72 to 0.94). There was 
no significant difference in the 28-day mortality rate 
among patients not receiving respiratory support 
[108]. These results strongly suggest that 
dexamethasone treatment is effective for a population 
of patients with COVID-19 requiring respiratory 
support. It is necessary to confirm these results among 
the participants who were diagnosed as COVID-19 
through viral RNA detection. In another RCT for 
severe COVID-19, patients receiving methyl-
prednisolone also showed a lower mortality rate 
compared to the control group [66]. 
Colchicine, an anti-inflammatory agent which is 
mainly used for gout and rheumatoid arthritis, has 
been used for a long time. It inhibits microtubule 
polymerization and mitosis in the metaphase [109]. It 
is promising that the effects of colchicine treatment 
were revealed in terms of survival, clinical 
improvement, and duration of hospitalization in the 
two RCTs for COVID-19 [70, 71]. If a larger-scale 
follow-up RCT is conducted, the effect might be 
further supported. 
Angiotensin-converting enzyme 2 (ACE2) is a 
transmembrane protein and the main entry point into 
cells for SARS-CoV-2. Theoretically, if the expression 
of ACE2 decreases, it will be a defense mechanism 
against the entry of the virus. On the other hand, 
ACE2 shows a protective action against virus-induce 
lung injury by converting angiotensin II to 
angiotensin-(1–7), which have a vasodilator effect 
[110, 111]. ACEI and ARB can induce up-regulation of 
ACE2 [112, 113], which might negatively affect the 
treatment of disease. Contrary, an in vivo study 
showed that SARS-CoV spike-mediated lung injury 
was attenuated by losartan [114]. For these conflicting 
evidences, there has been an interest in ACEI and 
ARB in relation to COVID-19. In one RCT for 
COVID-19 [72] and one meta-analysis including three 
non-RCTs on COVID-19 [73], participants who 
received ARB performed better in terms of discharge 
or survival. More RCTs on ACEI or ARB for 
COVID-19 in the group of patients with pre-existing 
hypertension or at risk for cardiovascular disease are 
still required. 
Routine administration of anticoagulants in 
sepsis or ARDS is not recommended currently. 
However, disseminated intravascular coagulation 
should still be the target of research to find treatments 
for sepsis or ARDS, because it is deeply involved in 





the pathogenesis and progress of these diseases. It has 
been reported that coagulopathy was associated with 
the prognosis of COVID-19 [115-117] and these results 
are consistent with what has been known in ARDS 
and sepsis. In a small-scale RCT of severe COVID-19, 
therapeutic anticoagulant therapy with enoxaparin 
showed a better outcome than prophylactic 
anticoagulant therapy [75]. More studies investigating 
the efficacy of augmenting these anticoagulation or 
thrombolytic treatments, while weighing the risk of 
hemorrhage, and narrowing the indications are 
required. 
Calcifediol is a main metabolite of vitamin D. 
Since lung epithelium expresses vitamin D receptors, 
administration of vitamin D may suppress the 
development of ARDS [118]. In a pilot RCT on 
COVID-19, treatment with a high dosage of calcifediol 
reduced the need for ICU admission [78]. 
CM4620-IE (AuxoraTM) is a selective small 
molecule inhibitor of calcium release-activated 
calcium (CRAC) channels. It was developed to 
prevent over-activation of CRAC channels that can 
lead to inflammatory diseases. It has been suggested 
that Auxora may protect against pulmonary 
endothelial damage and cytokine storm [119, 120]. 
This agent has been shown to be effective in terms of 
survival and clinical improvement in one small-scale 
RCT for severe or critical COVID-19 [79]. 
Ruxolitinib is a potent selective inhibitor of 
Janus-associated kinases 1 and 2 and has been used as 
a treatment for primary myelofibrosis, post- 
polycythemia vera or post-essential thrombocythemia 
myelofibrosis [121]. Ruxolitinib has a broad-spectrum 
of anti-inflammatory properties against cytokine 
storm mediated by IL-1, IL-6, IL-8, IL-12, tumor 
necrosis factor-α, IFN-γ, vascular endothelial growth 
factor, and granulocyte-macrophage colony- 
stimulating factor [122]. In an RCT on severe 
COVID-19, ruxolitinib showed higher rate of 
radiological improvement despite the small number 
of participants [81]. In this RCT, no one out of 20 
patients with severe COVID-19 in the treatment group 
died within 28 days, whereas three out of 21 patients 
in the control group died. Further research results for 
severe COVID-19 at high risk for cytokine storm need 
to be supplemented. 
Leflunomide, an isoxazole derivative, inhibits 
the T cell proliferation by blocking dihydroorotate 
dehydrogenase. This agent has been used in the 
treatment of rheumatoid arthritis and psoriatic 
arthritis, and has been attempted to treat BK virus, 
cytomegalovirus, HIV, and ebolavirus [123]. The only 
RCT evaluating leflunomide for COVID-19 enrolled 
only 10 participants, but showed an effect of 
shortening the viral shedding period [82]. Similarly, in 
a preprint observational study involving 27 
participants, leflunomide showed effects of 
promoting viral clearance and increasing discharge 
rate [124]. 
Interferon showed effects in a number of in vitro 
studies on SARS and MERS. In addition, three RCTs 
on IFN-β for COVID-19 demonstrated favorable 
results in terms of survival, clinical improvement, 
discharge from hospital, and viral clearance [44, 83, 
84]. Since interferon has been used as a combination 
therapy with antiviral agents in most cases, further 
research is needed to discover the antiviral agent that 
can show the greatest effect when administered in 
combination with interferon, as well as specific 
indications. 
Convalescent plasma contains pathogen-specific 
neutralizing antibodies that can neutralize viral 
particles, which provide passive immunity to the 
recipient. It is hypothesized that early convalescent 
plasma therapy enhances the patient's capability to 
clear the initial viral inoculum by neutralizing viral 
particles [125]. Convalescent plasma therapy has been 
applied to a wide range of infectious diseases such as 
diphtheria, pneumococcal pneumonia, hepatitis A 
and B, mumps, polio, measles, and rabies. The results 
of a meta-analysis on convalescent plasma treatment 
for SARS are relatively promising [12]. In one RCT for 
severe COVID-19, convalescent plasma treatment 
showed an effect in terms of clinical improvement 
[87]. In contrast, the effect of convalescent plasma 
treatment was not demonstrated in another RCT on 
moderate COVID-19 involving larger number of 
participants [89]. The differences in severity of 
COVID-19 in these two RCTs may have contributed to 
this contradiction. Therefore, a large-scale RCT on 
convalescent plasma treatment targeting severe 
COVID-19 is required. 
Intravenous immunoglobulin therapy provides 
passive immunity and has the property to modulate 
immune function. High doses of intravenous 
immunoglobulin can produce anti-inflammatory and 
inflammatory-modulating effects on a variety of 
immune cells, which can intervene and modulate the 
mechanisms of cytokine storm, and have been 
administered to treat various diseases such as 
immune thrombocytopenia purpura or Kawasaki 
disease [126]. The only preprint small-scale RCT on 
intravenous immunoglobulin therapy for COVID-19 
showed better clinical outcomes in the treatment 
group [91]. 
Our study has some limitations. RCTs for SARS 
and MERS were extremely rare. In the case of 
COVID-19, more RCTs were obtained. However, all 
except for eight RCTs included less than 100 
participants per each arm. Although we updated the 





latest search results for RCTs and meta-analyses on 
COVID-19, we did not include the latest search results 
for non-clinical studies on the three coronavirus 
diseases because of the vast amount of data. 
In addition, our study also highlights that 
treatments with potential effects seen in in vitro 
studies have not translated in positive in vivo or 
clinical studies. The 4-aminoquinoline derivatives 
showed effects in a number of in vitro studies, but not 
in in vivo and clinical studies. On the other hand, 
favipiravir showed unfavorable results in an in vitro 
study, while it showed effects in a clinical study. This 
contradiction between in vitro and in vivo studies or 
between pre-clinical and clinical studies does not help 
in the current situation where a therapeutic agent for 
COVID-19 must be discovered in a short amount of 
time. Therefore, it is important to design in vivo or 
clinical studies after a thorough understanding of 
drug pharmacology and in-depth consideration of 
how to link in vitro antiviral activity and drug 
exposure at the putative target site of action. Fan et al. 
demonstrated that in vitro EC50/EC90 values for 
hydroxychloroquine should be compared to the in 
vivo free extracellular tissue concentration, which is 
similar to the free plasma hydroxychloroquine 
concentration [127]. Advances in cell modeling tools 
for biological research are expected to further enrich 
preclinical research design, and also help promote the 
development of new therapies [128]. 
When a specific infection enters a pandemic 
state, group immunization through vaccine, rather 
than quarantine, is the most effective countermeasure. 
As of October 29, 2020, 201 candidate vaccines against 
SARS-CoV-2 are being developed. Among them, 45 
have entered clinical trials, and none has been 
approved for use yet [129]. 
Conclusion 
In this summary report, we synthesized the 
results of previous studies on the treatment of SARS, 
MERS, and COVID-19. There was no therapeutic 
agent that consistently resulted in positive outcomes 
across SARS, MERS, and COVID-19. Remdesivir 
showed a therapeutic effect for COVID-19 in two 
RCTs involving the largest number of total 
participants (n = 1,461). Other therapies that showed 
an effect in at least two RCTs for COVID-19 were 
sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), 
IFN-β1b (n = 193), and convalescent plasma therapy 
(n = 126). Further RCTs are required. 
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